Is Bimekizumab on the market?

Bimekizumab (Bimekizumab) is a humanized monoclonal antibody against IL-17. It was approved by the European Medicines Agency ( in August 2021) span>EMA) approved in the EU for the treatment of plaque psoriasis, it is the first IL-17 inhibitor targeting IL-17A and IL-17F. It has shown better efficacy in treating moderate to severe psoriasis than secukinumab, another IL-17 inhibitor, as well as ustekinumab, an IL-12/23 inhibitor, and adalimumab, a TNF inhibitor. It was also approved by the US Food and Drug Administration (FDA) in October 2023 and sold under the trade name Bimzelx.

The FDA's approval of meclizumab was supported by data from three Phase 3, multicenter, randomized, placebo and/or active-controlled trials. All studies met the co-primary endpoint and all graded secondary endpoints. Patients treated with bimeclizumab achieved higher levels of skin clearance at week 16 (ranked secondary endpoint, BE VIVID; p<0.0001) compared with patients treated with ustekinumab, placebo (co-primary endpoint, BE READY and BE VIVID; p>0.0001) and adalimumab (co-primary endpoint, BE SURE; p<0.001). Bimizumab is generally well tolerated.

The generic drug Bimeizumab has not yet been launched in the country, so it cannot be included in medical insurance. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.